https://www.semiconductor-digest.com/key-measures-of-global-semiconductor-manufacturing-industry-strength-improve-in-q1-2024-semi-reports/

recovery is here. don't wait

https://www.semiconductor-digest.com/key-measures-of-global-semiconductor-manufacturing-industry-strength-improve-in-q1-2024-semi-reports/

hard disk shortage and price increase is real

https://seekingalpha.com/news/4088285-western-digital-plans-to-raise-flash-hard-drive-prices-amid-supply-shortage

https://klse.i3investor.com/web/cube/blog/blposts/GrowthInvesting/Yusofff

Gogogo

https://jawplace.com/mrdiy-ipo-how-much-does-it-yield/

https://www.venturetech.my/portfolio-item/selia-tek-medical/

Esok boom.

Breakout. Masuk. TP 1.20

https://jawplace.com/lotte-chemical-titan-a-turnaround-story/

https://jawplace.com/ntpm-holdings-berhad-out-of-woods-or-too-soon/

nais deep dive. appreciate it

Time DotCom
Assuming the Company is able to generate 10-15% growth consistently over the years and couple with the continuous cash generation as per % of sales, with an average industry PE of 20 (conservative PE) the company could derive a fair value of RM 14.97 which is 37-38% upside from their current share price.
https://jawplace.com/the-growth-of-data-usage/

Careplus (investor briefing)

Turnover could easily exceed RM500 mil with current facility back to 90% utilisaton (in 2019 disrupted by plant modifications and changes for improvement) compared to 83% for FY 2019 (88% FY 2018) and the ASP increase could easily exceed 20% compared to 2019. You can buy upto price of 170.


My valuation based on PE15 to 18 using a projected ASP increase by 25% is from 223 to 267. However with a 20% increase, the valuation would be 180 to 216,
CAREPLUS

Catalyst for Investment and Investment Merits


• • Completion of disposal of 50% equity interest in Careplus (M) S/B (CMSB), a wholly owned subsidiary to Ansell for RM 27.0 mil, improving its net current liability position at 31 Dec 2019

• • Sale at 150% of the 50% Net Asset value of CMSB and realized a profit on disposal of about RM17.98mil which is about 3.07 Sen EPS in Q2 FY 2020.


• • Net proceeds of cash RM28.5 mil coming to Careplus after netting of additional share capital of RM10.5 mil for reinvestment in CMSB for subscription of new shares for expansion in CAPEX and repayment by CMSB of inter co loan of 12 mil


• Careplus’on-going structural transformation could translate into sustainable earnings growth.

• Margin expansion and improving profitability: Underpinned by high ASP (driven by COVID19 outbreak), lower raw mat cost and improved plat utilization rate

• The plant modification and improvement in FY 2019 will see plant utilization rate increased from 83% in 2019 to almost 90%

• Synergistic JV with Ansell: Leverage on Ansell’s global footprints and market leadership to sustain long term earnings growth


Careplus’s prospect has improved significantly with Ansell (world largest surgical glove brand) JV in CMSB (on a 50:50 basis) and earnings growth accelerated with increase capacity with 9 new production lines which will be commissioned by end 2020 and another 2 will be installed in 2021.

The JV will increase production capacity from 4.1 billion pcs to 5.6 bil pieces by end 2020 and 6.5 bil pieces by end of 2021 barring any interruption. A 52% increase in production capacity with 9 new production lines by 2022: Expected to add capacity by 2.2 bil pcs/year to achieve total capacity of 6.3bil pcs/year by year 2022 (4.1 bil 2019)

• Shifting to higher value product offering: Increasing production mix with higher value surgical gloves making about 30% of the total revenue compared to 5% in FY 2019

hoot time! pak tua is back

Careplus’s prospect has improved significantly with Ansell (world largest surgical glove brand) partnership and earnings growth accelerated by COVID-19

Join us for a Q1FY20 result briefing to understand how Careplus’ on-going structural transformation could translate into sustainable earnings growth.

Date: 9th June 2020
Time: 10:30 AM
Venue: Microsoft Teams

Company Overview
Listed in 2010, Careplus is a latex and nitrile rubber glove specialized manufacturer based in Seremban with 4.1bil output capacity. Post-Ansell JV, Careplus will produce higher value surgical gloves.

Investment Highlights
1. Margin expansion and improving profitability: Underpinned by high ASP (driven by COVID19 outbreak), lower raw mat cost and improved plant utilization rate (from 90% in 2019 to almost 100%)

2. Synergistic JV with Ansell: Leverage on Ansell’s global footprints and market leadership to sustain long term earnings growth
3. c.52% increase in production capacity with 9 new production lines by 2022: Expected to add capacity by 2.2 bil pcs/year to achieve total capacity of 6.3bil pcs/year by year 2022 (4.1 bil 2019A)

4. Shifting to higher value product offering: Increasing production mix with higher value surgical gloves

RSVP latest by 5th June 2020, Friday and we will send you a link to participate in the Conference Call. Seats are limited!
Thanks.

Rocket d careplus. Investor briefing my the MD on Tuesday. First investor briefing. If its not good why got briefing?

gogogo.. hoot up tmr.

Yes. thanks for confirmation. hope can collect more tomorrow.

hopefully dont limit up so fast. can accumulate.

Okay! i am in ! gogogogo.

LIMIT up tomorrow. operator gonna goreng. rumours of takeover.

HLT shoot shoot shoot. Hopw to get into early bird tmr!

pak tua believe hlt. gogogo hlt boom like adventa! pak tua never wrong

add me to the group please paktua73@30k

add me please

Tomorrow confirm gap up.. got chance queue higher d.. if hit above 90 cents possible to go back rm1.

Alot of people stuck at rm 90 cents above. correction 2 days. good to accumulate. if naik, keep for 2 days. watch tomorrow. tomorrow boom keep 2 days, t+2 above rm 1 sell

cun. msk 0.695 dh

N2n blh pegi lg?

Terima kasih ats sharing yvonne. Nova good company. Net cash. Tak yah risau.

follow by NOVA wellness. ikut sekali semua healthcare limit up besok

semua alive ke! naik baru alive. jom HUAT skl.